XOMA Royalty Corporation Stock Price, News & Analysis

XOMA Royalty Corporation (NASDAQ: XOMA) has acquired BioInvent International's future royalty and milestone rights for mezagitamab (TAK-079) in a deal worth up to $30 million. The transaction includes $20 million paid at closing and an additional $10 million contingent upon mezagitamab receiving FDA marketing approval for IgA nephropathy.

With this acquisition and its existing entitlements, XOMA will receive up to $16.25 million in milestones from Takeda and mid-single digit royalties on future mezagitamab commercial sales. Takeda is currently conducting a Phase 3 clinical trial for mezagitamab in immune thrombocytopenia (ITP) patients. The drug is a fully human IgG1 monoclonal antibody targeting CD38-expressing cells, with potential to become best-in-class in its category.

XOMA Royalty (NASDAQ: XOMA) reported strong Q1 2025 financial results with total income of $15.9 million, up from $1.5 million in Q1 2024. The company received $18.0 million in cash receipts, including $13.4 million in royalties and $4.6 million in milestones. Key achievements include the EMA's acceptance of tovorafenib's MAA, Takeda's Phase 3 trial initiation for mezagitamab, and acquisition of interest in Castle Creek's D-Fi through a $5 million investment. The company ended Q1 with $95.0 million in cash and reported net income of $2.4 million, compared to a net loss of $8.6 million in Q1 2024. XOMA continued its shareholder-focused strategy through share repurchases and pipeline advancement while maintaining strict expense control.

XOMA Royalty Corporation (NASDAQ: XOMA) announced its participation in two upcoming investor conferences. At the H.C. Wainwright 1st Annual Royalty Company Virtual Conference on May 13, 2025, CEO Owen Hughes and CIO Brad Sitko will lead multiple sessions. Hughes will participate in a fireside chat at 2:30 PM ET and join a panel on royalty model pros and cons at 4:00 PM ET. Sitko will discuss development-stage companies and royalty platforms at 5:00 PM ET.

Additionally, XOMA's business development team will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025. The presentations will be accessible through XOMA's investor relations website.

XOMA Royalty (NASDAQ: XOMA) has successfully completed the sale of all five pipeline assets acquired from its Kinnate Biopharma acquisition. The deal could yield up to $270 million in upfront and milestone payments, plus royalties ranging from low single digits to mid-teens on commercial sales.

The transaction follows XOMA's acquisition of Kinnate Biopharma on April 3, 2024. Under the agreement, holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all payments received by XOMA Royalty before April 2, 2029, including upfront payments, milestones, and royalties related to these assets.

XOMA Royalty (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference. Chief Investment Officer Brad Sitko will deliver a presentation on Wednesday, April 9, 2025, at 10:30 AM PT.

The presentation will be accessible through a dedicated link and the investor relations section of XOMA's website. Interested parties can access the replay, which will remain available for 90 days following the event.

XOMA Royalty (Nasdaq: XOMA) has announced quarterly cash dividend payments for its preferred stockholders. The company's Board of Directors has authorized dividends for two series of preferred stock:

- Holders of 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share

- Holders of 8.375% Series B Cumulative Perpetual Preferred Stock depositary shares (Nasdaq: XOMAO) will receive $0.52344 per depositary share, with each depositary share representing 1/1000 of a preferred share

Both dividend payments are scheduled for April 15, 2025, with a record date of April 3, 2025.

XOMA Royalty reported its Q4 and full year 2024 financial results, highlighting significant portfolio expansion and business achievements. The company doubled its royalty and milestone portfolio to over 120 assets through five transactions in 2024, including two whole company acquisitions.

Key financial metrics include:

• Q4 cash receipts: $4.0 million
• Full-year cash receipts: $46.3 million
• Q4 total income: $8.7 million
• Full-year total income: $28.5 million
• Year-end cash position: $106.4 million

Notable developments include FDA approvals for Day One's OJEMDA™ and Zevra's MIPLYFFA™. The company deployed $65 million to acquire new milestone and royalty assets and paid $5.5 million in dividends. However, XOMA recorded a net loss of $4.0 million in Q4 and $13.8 million for the full year 2024, primarily due to $30.9 million in non-cash credit losses on purchased receivables.

XOMA Royalty (NASDAQ: XOMA), a biotech royalty aggregator, has announced its Executive Team's upcoming participation in investor conferences scheduled for March 2025. The company will engage in one-on-one investor meetings during these events.

Presentations will be accessible through the investor relations section of XOMA's website (www.xoma.com). Each presentation will remain archived and available for replay on the site for a 90-day period following the respective events.

XOMA Royalty (NASDAQ: XOMA) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The virtual event will feature a fireside chat with CEO Owen Hughes and CIO Brad Sitko on February 11, 2025, at 3:20 PM ET.

The presentation will be accessible through a dedicated link and through XOMA's investor relations website section. Interested parties can access the replay of the presentation, which will remain archived on the company's website for 90 days following the event.